A365270 Stock Overview
Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
curacle co.,ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,340.00 |
| 52 Week High | ₩21,350.00 |
| 52 Week Low | ₩4,900.00 |
| Beta | 1.59 |
| 11 Month Change | 10.65% |
| 3 Month Change | 9.69% |
| 1 Year Change | -29.71% |
| 33 Year Change | -77.99% |
| 5 Year Change | n/a |
| Change since IPO | -79.31% |
Recent News & Updates
Is curacleltd (KOSDAQ:365270) Using Too Much Debt?
Nov 01
curacleltd (KOSDAQ:365270) Has Debt But No Earnings; Should You Worry?
Jun 26Is Curacle (KOSDAQ:365270) Using Too Much Debt?
Feb 27Shareholder Returns
| A365270 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 15.3% | -1.2% | -0.5% |
| 1Y | -29.7% | 44.3% | 7.2% |
Return vs Industry: A365270 underperformed the KR Biotechs industry which returned 44.3% over the past year.
Return vs Market: A365270 underperformed the KR Market which returned 7.2% over the past year.
Price Volatility
| A365270 volatility | |
|---|---|
| A365270 Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A365270 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A365270's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Jaehyeon Yoo | curacle.com |
Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels. Its products cover age-related vascular diseases, intractable metabolic diseases, and cancer targeting/immunotherapy. The company’s products in pipeline include CU06, which covers treatment and medical indications, such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke treatment, concomitantly used with immunotherapy, inflammatory bowel disease treatment, and hereditary angioedema; CU03, which is in Phase 2a clinical trial study for the treatment of age-related macular degeneration; and CU01, a diabetic nephropathy medicine that completed Phase 2a clinical trial.
curacle co.,ltd. Fundamentals Summary
| A365270 fundamental statistics | |
|---|---|
| Market cap | ₩87.96b |
| Earnings (TTM) | -₩15.82b |
| Revenue (TTM) | ₩4.04b |
21.8x
P/S Ratio-5.6x
P/E RatioIs A365270 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A365270 income statement (TTM) | |
|---|---|
| Revenue | ₩4.04b |
| Cost of Revenue | ₩15.49m |
| Gross Profit | ₩4.02b |
| Other Expenses | ₩19.84b |
| Earnings | -₩15.82b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14k |
| Gross Margin | 99.62% |
| Net Profit Margin | -391.74% |
| Debt/Equity Ratio | 53.6% |
How did A365270 perform over the long term?
See historical performance and comparison